KR102328327B1 - 심혈관 위험 사건 예측 및 이의 용도 - Google Patents

심혈관 위험 사건 예측 및 이의 용도 Download PDF

Info

Publication number
KR102328327B1
KR102328327B1 KR1020177007356A KR20177007356A KR102328327B1 KR 102328327 B1 KR102328327 B1 KR 102328327B1 KR 1020177007356 A KR1020177007356 A KR 1020177007356A KR 20177007356 A KR20177007356 A KR 20177007356A KR 102328327 B1 KR102328327 B1 KR 102328327B1
Authority
KR
South Korea
Prior art keywords
risk
biomarker
delete delete
sample
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177007356A
Other languages
English (en)
Korean (ko)
Other versions
KR20170062453A (ko
Inventor
데이빗 스터링
신타로 카토
에드워드 엔. 브로디
스티븐 에이. 윌리엄스
Original Assignee
소마로직, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 소마로직, 인크. filed Critical 소마로직, 인크.
Publication of KR20170062453A publication Critical patent/KR20170062453A/ko
Application granted granted Critical
Publication of KR102328327B1 publication Critical patent/KR102328327B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G06N7/005—
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q40/00—Finance; Insurance; Tax strategies; Processing of corporate or income taxes
    • G06Q40/08—Insurance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/205—Aptamer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Business, Economics & Management (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
KR1020177007356A 2014-09-26 2014-11-03 심혈관 위험 사건 예측 및 이의 용도 Active KR102328327B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055984P 2014-09-26 2014-09-26
US62/055,984 2014-09-26
PCT/US2014/063714 WO2016048388A1 (en) 2014-09-26 2014-11-03 Cardiovascular risk event prediction and uses thereof

Publications (2)

Publication Number Publication Date
KR20170062453A KR20170062453A (ko) 2017-06-07
KR102328327B1 true KR102328327B1 (ko) 2021-11-22

Family

ID=51982763

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177007356A Active KR102328327B1 (ko) 2014-09-26 2014-11-03 심혈관 위험 사건 예측 및 이의 용도

Country Status (9)

Country Link
US (2) US10670611B2 (enExample)
EP (1) EP3198023B1 (enExample)
JP (3) JP2017530356A (enExample)
KR (1) KR102328327B1 (enExample)
AU (1) AU2014407088B2 (enExample)
BR (1) BR112017005730B1 (enExample)
CA (2) CA2961340C (enExample)
ES (1) ES2792227T3 (enExample)
WO (1) WO2016048388A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7844609B2 (en) 2007-03-16 2010-11-30 Expanse Networks, Inc. Attribute combination discovery
US8108406B2 (en) 2008-12-30 2012-01-31 Expanse Networks, Inc. Pangenetic web user behavior prediction system
EP3276526B8 (en) 2008-12-31 2025-01-15 23andMe, Inc. Finding relatives in a database
CN106061391A (zh) * 2014-04-11 2016-10-26 株式会社日立制作所 医用图像摄影装置以及医用图像摄影方法
CN118522390A (zh) * 2016-04-01 2024-08-20 20/20基因系统股份有限公司 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物
WO2017214684A1 (en) * 2016-06-17 2017-12-21 Adelaide Research & Innovation Pty Ltd Methods and products for identifying conditions associated with cardiac fibrotic remodelling
KR102322258B1 (ko) 2017-05-19 2021-11-04 현대자동차 주식회사 마이크로폰 및 그 제조 방법
US11079394B2 (en) * 2017-07-25 2021-08-03 Vanderbilt University Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
WO2019074491A1 (en) * 2017-10-10 2019-04-18 Flagship Biosciences, Inc. PATIENT STRATIFICATION METHOD USING IMAGE ANALYSIS PARAMETER DELIVERY FUNCTIONS
US10503970B1 (en) 2017-12-11 2019-12-10 State Farm Mutual Automobile Insurance Company Method and system for identifying biometric characteristics using machine learning techniques
US10825564B1 (en) * 2017-12-11 2020-11-03 State Farm Mutual Automobile Insurance Company Biometric characteristic application using audio/video analysis
BR112020011454A2 (pt) * 2017-12-13 2021-02-09 F. Hoffmann-La Roche Ag métodos para prever o risco de acidente vascular, para prever o risco de acidente vascular cerebral e para aprimorar a precisão da previsão e usos do (i) biomarcador ang-2 e/ou do biomarcador igfbp7
US11317872B2 (en) * 2017-12-15 2022-05-03 Mayo Foundation For Medical Education And Research Predicting transient ischemic events using ECG data
US20190295727A1 (en) * 2018-03-23 2019-09-26 American Heart Association, Inc. System and Method for Assessing Heart Health and Communicating the Assessment to a Patient
CN113474358A (zh) * 2019-02-08 2021-10-01 日本电气株式会社 人t细胞白血病病毒1型(htlv-1)相关疾病的诊断方法
TWI741914B (zh) * 2019-03-06 2021-10-01 國立清華大學 檢測心血管疾病的檢驗套組及心血管疾病相關生物標記的濃度檢測方法
TWI741915B (zh) * 2019-03-06 2021-10-01 國立清華大學 檢測心血管疾病的檢驗套組及心血管疾病相關生物標記的濃度檢測方法
TWI716827B (zh) * 2019-03-06 2021-01-21 國立清華大學 檢測心血管疾病的檢驗套組及心血管疾病相關生物標記的濃度檢測方法
CN110068676A (zh) * 2019-03-22 2019-07-30 同济大学 分泌蛋白Serpin A3在预测心肌损伤诊断试剂中的应用
US20220349904A1 (en) * 2019-09-03 2022-11-03 Somalogic Operating Co., Inc. Cardiovascular Risk Event Prediction and Uses Thereof
JP7215682B2 (ja) * 2019-09-09 2023-01-31 ａｉｗｅｌｌ株式会社 情報処理システムおよびプログラム
CN110838339B (zh) * 2019-09-23 2023-05-05 广东工业大学 邻苯二甲酸酯对斑马鱼毒性效应的预测方法、设备及介质
WO2021070649A1 (ja) * 2019-10-10 2021-04-15 ソニー株式会社 表示制御装置、表示制御方法、及び、プログラム
JP7700114B2 (ja) * 2019-11-15 2025-06-30 ゲイシンガー クリニック ヘルスケア集団の管理に対する機械学習手法のためのシステムおよび方法
US10902955B1 (en) 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
WO2021243166A2 (en) * 2020-05-28 2021-12-02 The Regents Of The University Of Michigan Deterimining risk of spontaneous coronary artery dissection and myocardial infarction and systems and methods of use thereof
US11416776B2 (en) * 2020-08-24 2022-08-16 Kpn Innovations, Llc. Method of and system for identifying and enumerating cross-body degradations
KR20230085151A (ko) * 2020-10-20 2023-06-13 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 심혈관 사건 위험 예측
JP2024508975A (ja) * 2021-03-08 2024-02-28 サノフイ 心血管疾患
EP4430635A1 (en) * 2021-11-11 2024-09-18 Beckman Coulter, Inc. Assessment of risk for major adverse cardiac event
CN114445445B (zh) * 2022-04-08 2022-07-01 广东欧谱曼迪科技有限公司 Ct图像的动脉分割方法、装置、电子设备及存储介质
CN117594131B (zh) * 2024-01-17 2024-04-16 北京市心肺血管疾病研究所 用于鉴别或辅助鉴别急性胸痛类型的装置及其应用
WO2025230312A1 (ko) * 2024-04-30 2025-11-06 주식회사 메디웨일 전신질환 위험도 기반 대상체 맞춤형 처방 지원 방법 및 장치
CN118152994B (zh) * 2024-05-11 2024-07-16 四川开物信息技术有限公司 一种安全因素影响计算方法
CN119517393A (zh) * 2024-10-29 2025-02-25 中国疾病预防控制中心慢性非传染性疾病预防控制中心 脑卒中发病风险评估方法及系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002677A2 (en) 2005-06-24 2007-01-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
WO2008076269A2 (en) 2006-12-13 2008-06-26 Gilead Sciences, Inc. MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS
US20110144914A1 (en) 2009-12-09 2011-06-16 Doug Harrington Biomarker assay for diagnosis and classification of cardiovascular disease

Family Cites Families (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642284A (en) 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US6287793B1 (en) 1988-08-19 2001-09-11 Elan Pharmaceuticals, Inc. Diagnostic methods for alzheimer's disease
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
AT398004B (de) 1992-04-14 1994-08-25 Berbi Gmbh Verfahren zur bestimmung von plasmin-alpha2- antiplasmin-komplexen unter verwendung eines komplexspezifischen monoklonalen antikörpers
EP0574599A1 (en) 1992-06-13 1993-12-22 BEHRINGWERKE Aktiengesellschaft Process for the detection of complexed cathepsin G and alpha-1-antichymotrypsin
EP0699306B1 (en) 1993-05-17 1999-09-08 Fortron Bioscience, Inc. Assay for cardiac troponin i
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
DK0776337T3 (da) 1994-07-08 2005-12-12 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-11
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
FR2729759A1 (fr) 1995-01-19 1996-07-26 Pasteur Sanofi Diagnostics Procede de dosage ultrasensible de la troponine i cardiaque
ATE273384T1 (de) 1995-04-06 2004-08-15 Regeneron Pharma Tie-2 liganden, herstellungsverfahren und verwendung
US5795725A (en) 1995-04-18 1998-08-18 Biosite Diagnostics Incorporated Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
US6991907B1 (en) 1995-04-18 2006-01-31 Biosite, Inc. Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays
US6627404B1 (en) 1995-04-18 2003-09-30 Biosite, Inc. Methods for improving the recovery of troponin I and T in membranes, filters and vessels
DE69633780T3 (de) 1995-04-18 2011-05-05 Biosite Incorporated, San Diego Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays
FI104857B (fi) 1996-01-15 2000-04-14 Hytest Oy Sydänlihaksen soluvaurioiden asteen mittaus immunokemiallisella menetelmällä sisältäen menetelmään soveliaat vasta-aineet
US7285418B2 (en) 1996-06-25 2007-10-23 Hytest Ltd. Method and kit for the diagnosis of troponin I
EP0938678B1 (en) 1996-06-25 2003-09-03 OY Aboatech AB Method and kit for the diagnosis of troponin i
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US6156521A (en) 1997-12-19 2000-12-05 Biosite Diagnostics, Inc. Methods for the recovery and measurement of troponin complexes
WO1998029726A2 (en) 1996-12-27 1998-07-09 Coulter International Corp. Method of detecting and determining the concentration of total troponin i in a biological sample
US6670196B1 (en) 1997-05-14 2003-12-30 Biosite, Inc. Rapid evaluation of the ratio of biological molecules
US7384751B1 (en) 1997-07-16 2008-06-10 Queen's University At Kingston Methods of diagnosing muscle damage
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
AU6117099A (en) 1998-10-21 2000-05-08 Spectral Diagnostics Inc. Cardiac troponin i polypeptide fragments and uses in diagnostics
US20020110523A1 (en) 1999-03-23 2002-08-15 Cornelis Kluft Methods for screening or monitoring the risk of cardiovascular disease relating to sex steroid compound or composition intake and methods for screening sex steroid compound
US20030077668A1 (en) 1999-07-22 2003-04-24 Ikagaku Co., Ltd. Method for arteriosclerosis diagnosis
US7618782B1 (en) 1999-10-18 2009-11-17 Queen's University At Kingston Methods of diagnosing muscle damage
US20050272055A1 (en) 2000-02-01 2005-12-08 Rina Das Method of treating lethal shock induced by toxic agents and diagnosing exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
US20030040505A1 (en) 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
AUPR005600A0 (en) 2000-09-12 2000-10-05 University Of Sydney, The Diagnostic assay
EP2322648A1 (en) 2000-09-26 2011-05-18 Duke University RNA aptamers and methods for identifying the same
WO2002063302A1 (en) 2001-02-07 2002-08-15 Immunomatrix Inc. A method for reducing heparin interference in diagnostic tests for cardiac troponin
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20030199000A1 (en) 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US7524635B2 (en) 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
EP1666881B1 (en) 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
US20020197741A1 (en) 2001-05-11 2002-12-26 Sabucedo Albert J. Method of determining time of death
IL159053A0 (en) 2001-05-25 2004-05-12 Univ Duke Modulators of pharmacological agents
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US20030003503A1 (en) 2001-06-29 2003-01-02 Tsai Tenlin S. Enhancing sensitivity and equimolar detection through modifications of the reaction environment
US20040186359A1 (en) 2001-07-09 2004-09-23 Beaudoin Stephen P. Afinity biosensor for monitoring biological process
US7608406B2 (en) 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US6461828B1 (en) 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
JP2005510696A (ja) 2001-11-27 2005-04-21 ダイアジェニクス インターナショナル コーポレーション 患者サンプル中の生化学的標識の迅速同時検出のための免疫分析法および免疫分析キット
US7371582B2 (en) 2002-01-23 2008-05-13 Boditechmed Inc. Lateral flow quantitative assay method and strip and laser-induced fluorescence detection device therefor
DE10211818B4 (de) 2002-03-16 2006-07-06 peS Gesellschaft für medizinische Diagnose-Systeme mbH Verfahren zur quantitativen Bestimmung mehrerer Analyten
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
EP1572937B1 (en) 2002-04-09 2012-02-08 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
SI2336359T1 (sl) 2002-05-09 2016-08-31 The Brigham And Women's Hospital, Inc. 1L1RL-1 kot marker kardiovaskularne bolezni
AU2003268905A1 (en) 2002-05-21 2003-12-02 Mtm Laboratories Ag G - protein coupled receptor marker molecules associated with colorectal lesions
WO2004005924A1 (en) 2002-07-03 2004-01-15 Spinelix 3d microarray
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
EP2386862A1 (en) 2002-10-09 2011-11-16 DMI Biosciences, Inc. Methods and kits for diagnosing appendicitis
US7135329B2 (en) 2002-11-18 2006-11-14 Princeton Biomeditech Corporation Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
EP1620567A1 (en) 2003-04-15 2006-02-01 Hans-Jürgen Thiesen Method for diagnosing rheumatoid arthritis or osteoarthritis
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
WO2004108896A2 (en) 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
US7927795B2 (en) 2003-06-09 2011-04-19 Board Of Trustees Of The University Of Arkansas Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
US10179935B2 (en) 2003-07-17 2019-01-15 Pacific Edge Limited Markers for detection of gastric cancer
WO2005024603A2 (en) 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
US20050181386A1 (en) 2003-09-23 2005-08-18 Cornelius Diamond Diagnostic markers of cardiovascular illness and methods of use thereof
US7634360B2 (en) 2003-09-23 2009-12-15 Prediction Sciences, LL Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
US20080010024A1 (en) 2003-09-23 2008-01-10 Prediction Sciences Llp Cellular fibronectin as a diagnostic marker in cardiovascular disease and methods of use thereof
US7392140B2 (en) 2003-09-23 2008-06-24 Prediction Sciences, Llc Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
WO2005033327A2 (en) 2003-09-29 2005-04-14 Biosite Incorporated Methods and compositions for the diagnosis of sepsis
DE10349124A1 (de) 2003-10-22 2005-05-19 Roche Diagnostics Gmbh Differenzialdiagnostik mit Hepcidin
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
EP1530047A1 (en) 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
AU2004294178C1 (en) 2003-11-19 2011-10-27 Rules-Based Medicine, Inc. Methods for diagnosis, stratification, and monitoring of Alzheimer's disease
US20050164409A1 (en) 2003-12-10 2005-07-28 Kiernan Urban A. Method and apparatus for mass spectrometric immunoassay analysis of specific biological fluid proteins
US8932808B1 (en) 2004-01-21 2015-01-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
EP1723428A2 (en) 2004-02-19 2006-11-22 Yale University Corporation Identification of cancer protein biomarkers using proteomic techniques
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
JP2007532662A (ja) 2004-04-13 2007-11-15 （オーエスアイ）アイテツク・インコーポレーテツド 高分子量の立体的な基へ抱合された核酸アプタマー
EP1747282B1 (en) 2004-04-15 2011-06-08 University of Florida Research Foundation, Inc. Map-2 proteolytic breakdown products as diagnostic biomarkers for neural injury
DK1745287T3 (da) 2004-05-11 2011-01-24 Univ Pittsburgh Diagnostisering og monitorering af inflammatoriske sygdomme ved at måle komplementkomponenter på hvide blodlegemer
US20060039863A1 (en) 2004-07-22 2006-02-23 Michael Schirner Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
US20080090759A1 (en) 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
US20060134698A1 (en) 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
WO2006069073A2 (en) 2004-12-20 2006-06-29 The General Hospital Corporation Use of angiopoietins in anti-tumor therapy
JP4734654B2 (ja) 2004-12-27 2011-07-27 国立大学法人 岡山大学 妊娠中毒症の検査方法
US8178505B2 (en) 2005-01-05 2012-05-15 Sloan-Kettering Institute For Cancer Research Method of predicting and reducing risk of metastasis of breast cancer to lung
US20060199280A1 (en) 2005-03-03 2006-09-07 David Bar-Or Quantification of proteins
EP1875248A2 (en) 2005-03-29 2008-01-09 Inverness Medical Switzerland GmbH Device and method of monitoring a patient
ES2743543T3 (es) 2005-05-05 2020-02-19 Univ Drexel Diagnóstico de patología hepática a través de la evaluación del quininógeno fucosilado
GB0509305D0 (en) 2005-05-06 2005-06-15 Randox Lab Ltd Method
US20060275849A1 (en) 2005-06-07 2006-12-07 Beckman Coulter, Inc. Monoclonal antibody reagents
EP1904657B1 (en) 2005-06-08 2011-05-25 Hitachi Chemical Research Center, Inc. METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES
EP1888765A4 (en) 2005-06-09 2008-11-05 Biosite Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS OF VENOUS THROMBOEMBOLIC ILLNESSES
CN101213451B (zh) 2005-06-28 2013-04-03 Zbx公司 膜阵列和分析设备
US20070218498A1 (en) 2005-08-30 2007-09-20 Buechler Kenneth F Use of soluble FLT-1 and its fragments in cardiovascular conditions
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
CA2624569A1 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US7947437B2 (en) 2005-10-17 2011-05-24 Sword Diagnostics, Inc. Methods for detecting organisms and enzymatic reactions using raman spectroscopy
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
CA2629388A1 (en) 2005-11-10 2007-05-18 Synergenz Bioscience Limited Methods and compositions for the assessment of cardiovascular function and disorders
US7908090B2 (en) 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
US20140273007A1 (en) 2013-03-12 2014-09-18 Dr. Susan Love Research Foundation Devices and methods for screening nipple aspirate for markers indicative of risk of developing breast cancer
US20070134814A1 (en) 2005-12-09 2007-06-14 Kajander E O Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease
WO2007070021A1 (en) 2005-12-09 2007-06-21 Nanobac Pharmaceuticals Incorporated Detection of calcifying nano-particles, and associated proteins thereon
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
WO2007103568A2 (en) 2006-03-09 2007-09-13 Biosite, Inc. Methods and compositions for the diagnosis of diseases of the aorta
AU2007227251A1 (en) 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
EP2016394A4 (en) 2006-04-04 2013-04-24 Singulex Inc METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
ES2646142T3 (es) 2006-04-24 2017-12-12 Critical Care Diagnostics, Inc. Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2
WO2007130673A2 (en) 2006-05-05 2007-11-15 Beth Israel Deaconess Medical Center Methods for the diagnosis and treatment of female infertility using molecular markers
EP2021512A4 (en) 2006-05-08 2009-08-05 Tethys Bioscience Inc SYSTEMS AND METHODS FOR DEVELOPING DIAGNOSTIC TESTS BASED ON BIOMARKER INFORMATION FROM SURGICAL CLINICAL SAMPLES
US20080118924A1 (en) 2006-05-26 2008-05-22 Buechler Kenneth F Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
MX2009001079A (es) 2006-07-28 2009-02-10 Adlyfe Inc Sondas de peptido para diagnosis y terapeutica.
EP1887361A1 (en) 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
ES2457243T3 (es) 2006-09-08 2014-04-25 The Chancellor, Masters And Scholars Of The University Of Oxford Diagnóstico clínico de una fibrosis hepática utilizando APOL1 de suero humano como biomarcador
EP2074223A4 (en) 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS
BRPI0717803A2 (pt) 2006-10-06 2013-11-19 Nestec Sa Composições e ensaios multiplicadores para a medição de mediadores biológicos de saúde fisiológica
US20080305512A1 (en) 2006-10-26 2008-12-11 Mattingly Phillip G Assay for cardiac troponin autoantibodies
US7776605B2 (en) 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
EP2129795A4 (en) 2006-12-19 2010-10-20 Synergenz Bioscience Ltd METHODS AND COMPOSITIONS FOR ASSESSING FUNCTION AND CARDIOVASCULAR DISORDERS
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
JP5439187B2 (ja) 2006-12-20 2014-03-12 アンチボディショップ・アクティーゼルスカブ 抗炎症性剤および／または抗凝固剤による治療的介入についての要件を決定するための敗血症患者の評価
CA2710286A1 (en) 2006-12-22 2008-07-03 Aviir, Inc. Two biomarkers for diagnosis and monitoring of atherosclerotic cardiovascular disease
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
EP2147115A4 (en) 2007-04-16 2010-05-05 CARDIOBIOINDEX / CARDIOBIOSCORE AND THE USE OF THE SPOKING PROTEOME IN CARDIOVASCULAR DIAGNOSTICS
US7901888B2 (en) 2007-05-09 2011-03-08 The Regents Of The University Of California Multigene diagnostic assay for malignant thyroid neoplasm
US8628929B2 (en) 2007-05-10 2014-01-14 Acorda Therapeutics, Inc. Methods for detecting cardiac damage
CA2696431C (en) 2007-07-17 2021-01-05 Somalogic, Inc. Method for generating aptamers with improved off-rates
EP2019318A1 (en) 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
WO2010012509A1 (en) 2008-08-01 2010-02-04 Bio-Rad Pasteur Method for the in vitro diagnosis of stroke
WO2009036123A1 (en) 2007-09-11 2009-03-19 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
CA2707986A1 (en) 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
GB0724735D0 (en) 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
US20090299155A1 (en) 2008-01-30 2009-12-03 Dexcom, Inc. Continuous cardiac marker sensor system
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009108073A1 (en) 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
AU2009234106A1 (en) 2008-03-05 2009-10-15 Singulex, Inc. Methods and compositions for highly sensitive detection of molecules
WO2009111033A2 (en) 2008-03-05 2009-09-11 Axela Inc. Detection of biomarkers and biomarker complexes
WO2009118185A1 (en) 2008-03-27 2009-10-01 Universitätsklinikum Heidelberg Peptides derived from cardial troponin i and their use as prognostic and diagnostic markers for heart failure
HUE039963T2 (hu) 2008-04-18 2019-02-28 Critical Care Diagnostics Inc Súlyos káros szívesemények rizikójának elõrejelzése
FR2934767B1 (fr) 2008-08-06 2011-11-25 Assist Publ Hopitaux De Paris Nouveau procede de pronostic associe aux cas d'hemorragies post-partum.
GB0818660D0 (en) 2008-10-10 2008-11-19 Cambridge Entpr Ltd Biomarkers
WO2010045463A2 (en) 2008-10-15 2010-04-22 Government Of The United States As Represented By The Secretary Of The Army Clinical decision model
WO2010048304A2 (en) 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
JP2012506245A (ja) 2008-10-24 2012-03-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 鉱質コルチコイドレセプターの活性化のバイオマーカー
WO2013022995A2 (en) 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
ES2573954T3 (es) 2008-12-30 2016-06-13 Children's Medical Center Corporation Método de predicción de apendicitis aguda
CN105388293A (zh) 2008-12-31 2016-03-09 雅培医护站股份有限公司 用于使用核苷酸缀合物的免疫测定的方法和设备
AU2009339152B2 (en) 2009-01-30 2015-11-19 Bio-Rad Europe Gmbh Method for the in vitro diagnosis of stroke
US20100216256A1 (en) 2009-02-17 2010-08-26 Florida State University Research Foundation Nanobelt-based sensors and detection methods
CN102326081B (zh) 2009-02-24 2014-11-19 霍夫曼-拉罗奇有限公司 s-ErbB-3作为癌症标志物的应用
WO2010129302A1 (en) 2009-04-28 2010-11-11 Innovative Laboratory Technologies, Inc. Lateral-flow immuno-chromatographic assay devices
JP5678045B2 (ja) 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド 高感度バイオマーカーパネル
US20100323380A1 (en) 2009-06-10 2010-12-23 Tufts Medical Center, Inc. Methods for diagnosing blood vessel reocclusion
WO2011017077A2 (en) 2009-07-27 2011-02-10 Trustees Of Boston University Nanochannel-based sensor system with controlled sensitivity
WO2011022628A1 (en) 2009-08-20 2011-02-24 The Board Of Regents Of The University Of Texas System Methods and compositions for diagnosis of acute myocardial infarction (ami)
WO2011026017A1 (en) 2009-08-31 2011-03-03 Abbott Laboratories Biomarkers for prediction of major adverse cardiac events and uses thereof
US10041939B2 (en) 2009-09-23 2018-08-07 Minicare B.V. Binding assay with multiple magnetically labelled tracer binding agents
US8846414B2 (en) 2009-09-29 2014-09-30 Advanced Liquid Logic, Inc. Detection of cardiac markers on a droplet actuator
US20120231472A1 (en) 2009-11-07 2012-09-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130116135A1 (en) 2009-11-24 2013-05-09 Commonweath Scientific And Industrial Research Organisation Methods, Kits and Reagents for Diagnosing, Alding Diagnosis and/or Monitoring Progression of a Neurological Disorder
US8652788B2 (en) 2009-12-02 2014-02-18 Abbott Laboratories Assay for diagnosis of cardiac myocyte damage
US20110136141A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
WO2011077333A1 (en) 2009-12-23 2011-06-30 Koninklijke Philips Electronics N.V. Analyte measurement apparatus and method
CN102812362B (zh) 2010-01-08 2015-02-11 卡瓦迪斯有限责任公司 用于预测心血管事件的外来体生物标志物的确定
WO2011089152A1 (en) 2010-01-20 2011-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity
WO2011097541A2 (en) 2010-02-05 2011-08-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011103330A2 (en) 2010-02-17 2011-08-25 The Johns Hopkins University Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury
WO2011123386A1 (en) 2010-03-28 2011-10-06 Samar Kumar Kundu Methods for detecting raman scattering using aromatic compounds comprising phosphate and at least one non-laser light source
EP2372364A1 (en) 2010-03-31 2011-10-05 Medizinische Hochschule Hannover Biomarker for pulmonary hypertension
CA2798149A1 (en) 2010-05-06 2011-11-10 Singulex, Inc Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis
WO2011143574A2 (en) 2010-05-14 2011-11-17 The Trustees Of The University Of Pennsylvania Plasma biomarkers for diagnosis of alzheimer's disease
MX2013000220A (es) 2010-06-23 2013-03-22 Astute Medical Inc Metodos y composiciones para diagnóstico y pronóstico de lesión renal e insuficiencia renal.
WO2011163661A1 (en) 2010-06-25 2011-12-29 Massachusetts Institute Of Technology Implantable magnetic relaxation sensors and methods of measuring a sensor's cumulative exposure to a biomarker
ES2387292B1 (es) 2010-06-29 2013-10-30 Fundacio Institut De Recerca Hospital Universitari Vall D'hebron Combinacion de snps para determinar el riesgo de sufrir una enfermedad neurovascular
MX355020B (es) 2010-07-09 2018-04-02 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
US20120015904A1 (en) * 2010-07-14 2012-01-19 Regents Of The University Of California Biomarkers for diagnosis of transient ischemic attacks
US20120142632A1 (en) 2010-08-04 2012-06-07 St. Vincent's Institute Of Medical Research Diagnostic and prognostic assay
WO2012019109A1 (en) 2010-08-05 2012-02-09 Abbott Point Of Care Inc. Oscillating immunoassay method and device
WO2012019104A1 (en) 2010-08-05 2012-02-09 Abbott Point Of Care Inc. Immunoassay method and device with magnetically susceptible bead capture
US20120040858A1 (en) * 2010-08-13 2012-02-16 Morehouse School Of Medicine Biomarkers for stroke
EP3225994A1 (en) 2010-08-26 2017-10-04 Roche Diagnostics GmbH Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure
ES2688048T3 (es) 2010-09-27 2018-10-30 Somalogic, Inc. Biomarcadores del mesotelioma y usos de los mismos
WO2012052757A1 (en) 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
US20120115175A1 (en) 2010-11-05 2012-05-10 Tufts Medical Center, Inc. Methods for diagnosing elevated right or left ventricular filling pressure
CA2817847C (en) 2010-11-12 2018-02-13 The Johns Hopkins University Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
WO2012094658A2 (en) 2011-01-08 2012-07-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012106152A1 (en) 2011-02-03 2012-08-09 Abbott Laboratories Methods of prognosis and diagnosis in chronic heart failure
US20140024046A1 (en) 2011-02-18 2014-01-23 Cavadis B.V. Exosomal Biomarkers for Cardiovasular Events
EP2678448A4 (en) 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
WO2012122374A2 (en) 2011-03-08 2012-09-13 Children's Medical Center Corporation Non-invasive methods for diagnosing chronic organ transplant rejection
FI20115367A0 (fi) 2011-04-15 2011-04-15 Hytest Oy Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
JP2014514572A (ja) 2011-04-29 2014-06-19 キャンサー・プリヴェンション・アンド・キュア，リミテッド 分類システムおよびそのキットを使用した肺疾患の同定および診断方法
EP2532748B1 (en) 2011-06-07 2014-10-08 Postech Academy-industry Foundation DNA aptamer specifically binding to human cardiac troponin I
US9387236B2 (en) 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
CN103796669B (zh) 2011-07-18 2016-11-09 重症监护诊断股份有限公司 治疗心血管疾病和预测运动疗法功效的方法
US20140242084A1 (en) 2011-08-08 2014-08-28 Nanyang Technological University Angiopoietin-Like 4 and Its Use in Modulating Cell Leakiness
WO2013036913A1 (en) 2011-09-08 2013-03-14 Nexus Dx, Inc. A multilevel analyte assay
BR122019023720B1 (pt) 2011-09-30 2023-01-24 Somalogic Operating Co., Inc Kit de triagem de um indivíduo em uma população por meio de avaliação ou prognóstico do risco de um evento cardiovascular futuro dentro de um período de 5 anos
EP2594942A1 (en) 2011-11-16 2013-05-22 Koninklijke Philips Electronics N.V. Long rigid spacers to enhance binding kinetics in immunoassays
EP2594940A1 (en) 2011-11-16 2013-05-22 Koninklijke Philips Electronics N.V. Particle repulsion to enhance surface contact in magnetic particle immunoassays
WO2013085367A1 (en) 2011-12-09 2013-06-13 Kyungpook National University Industry-Academic Cooperation Foundation Cardiac troponin i-targeting peptide and use thereof
US8986530B2 (en) 2012-01-09 2015-03-24 Washington State University Sample analysis systems, devices, and associated methods of operation
US9140695B2 (en) 2012-01-18 2015-09-22 University Of Utah Research Foundation Methods for analysis of free and autoantibody-bound biomarkers and associated compositions, devices, and systems
CA2957365A1 (en) 2012-02-27 2013-09-06 University Health Network (Uhn) Biomarkers for early determination of a critical or life threatening response to illness and monitoring response to treatment thereof
ES2650387T3 (es) * 2012-03-14 2018-01-18 Ruprecht-Karls-Universität Heidelberg Firmas epigenéticas como marcador de cardiomiopatías e insuficiencias miocárdicas
EP3968026A1 (en) 2012-03-26 2022-03-16 XCellCure, LLC Device and method for detection of analytes
EP2834638B1 (en) 2012-04-02 2020-02-12 Astute Medical, Inc. Methods for diagnosis and prognosis of sepsis
CA2870810A1 (en) 2012-04-18 2013-10-24 The University Of British Columiba Biomarkers for recovered heart function
WO2013163345A1 (en) 2012-04-24 2013-10-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
WO2013162368A1 (en) 2012-04-26 2013-10-31 Stichting Vu-Vumc Biomarkers
WO2013169890A1 (en) 2012-05-08 2013-11-14 Bg Medicine, Inc. Systems and methods for assessing disease risk, status, and prognosis
ITMI20120865A1 (it) 2012-05-18 2013-11-19 Antonio Bertolotto Biomarcatori per patologie del sistema nervoso centrale
JP6302896B2 (ja) 2012-05-18 2018-03-28 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法
US9482616B2 (en) 2012-06-06 2016-11-01 Board of Regents of the Nevada System of Higher Education, on behalf the University of Nevada, Reno Methods, kits and systems for signal amplification for bioassays using zinc nanoparticles
US10175250B2 (en) 2012-06-11 2019-01-08 Gabriela Venturini Da Silva Nitrated cardiac troponin I as a biomarker of cardiac ischemia
US20150203916A1 (en) 2012-06-27 2015-07-23 Music Foundation For Research Development Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm
AU2013302451B2 (en) 2012-08-16 2019-01-17 Critical Care Diagnostics, Inc. Methods for predicting risk of developing hypertension
US20140120551A1 (en) 2012-10-29 2014-05-01 Academia Sinica Methods of diagnosing, predicting and treating cardiovascular disease
WO2014093397A1 (en) 2012-12-12 2014-06-19 Green Domain Design, Llc Assay apparatus
WO2014116708A1 (en) 2013-01-22 2014-07-31 Singulex, Inc. Endothelin in the diagnosis of cardiac disease
WO2014122467A1 (en) 2013-02-06 2014-08-14 Loxbridge Research Llp Systems and methods for early disease detection and real-time disease monitoring
WO2014127265A1 (en) 2013-02-14 2014-08-21 Singulex, Inc. Non-invasive methods to determine vulnerable plaque burden in subjects
WO2014144605A1 (en) 2013-03-15 2014-09-18 Myriad Genetics, Inc. Biomarkers for major depressive disorder
WO2014187884A2 (en) 2013-05-22 2014-11-27 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for heart failure
WO2015034897A1 (en) * 2013-09-03 2015-03-12 Mayo Foundation For Medical Education And Research Reducing the risk of major adverse cardiac events
GB201315943D0 (en) 2013-09-06 2013-10-23 Randox Lab Ltd Risk stratification of suspected ami patients
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
US10794917B2 (en) 2013-09-20 2020-10-06 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
WO2015042593A1 (en) 2013-09-23 2015-03-26 Assaypro, Llc Immunoassays using over-labeled fluorescent probes
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US10017566B2 (en) * 2013-11-12 2018-07-10 The Brigham And Women's Hospital, Inc. Growth differentiation factor (GDF) for treatment of diastolic heart failure
US20160305959A1 (en) * 2013-11-14 2016-10-20 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN Detection of atherosclerotic cardiovascular disease risk
WO2015085368A1 (en) 2013-12-10 2015-06-18 The University Of Queensland Kits and methods for the diagnosis, treatment, prevention and monitoring of diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002677A2 (en) 2005-06-24 2007-01-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
WO2008076269A2 (en) 2006-12-13 2008-06-26 Gilead Sciences, Inc. MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS
US20110144914A1 (en) 2009-12-09 2011-06-16 Doug Harrington Biomarker assay for diagnosis and classification of cardiovascular disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
American Journal of Cardiology (2007) 100(1):23-27
American Journal of Medicine (2008) 121(1):50-57

Also Published As

Publication number Publication date
JP2022008847A (ja) 2022-01-14
AU2014407088B2 (en) 2021-09-23
CA2961340C (en) 2023-10-17
JP2017530356A (ja) 2017-10-12
AU2014407088A1 (en) 2017-03-16
CA2961340A1 (en) 2016-03-31
US10670611B2 (en) 2020-06-02
WO2016048388A1 (en) 2016-03-31
JP7270696B2 (ja) 2023-05-10
EP3198023A1 (en) 2017-08-02
BR112017005730B1 (pt) 2023-12-12
BR112017005730A8 (pt) 2022-10-18
US20180188267A1 (en) 2018-07-05
BR112017005730A2 (pt) 2017-12-19
JP2019207249A (ja) 2019-12-05
KR20170062453A (ko) 2017-06-07
CA3103560A1 (en) 2016-03-31
JP6956762B2 (ja) 2021-11-02
ES2792227T3 (es) 2020-11-10
EP3198023B1 (en) 2020-04-22
CA3103560C (en) 2023-01-17
US20160091499A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
JP7270696B2 (ja) 心血管系のリスクイベントの予測及びその使用
KR102111624B1 (ko) 심혈관 위험 사건 예측 및 그것의 용도
JP7712913B2 (ja) 心血管リスク／イベントの予測及びその使用
EP4232825B1 (en) Cardiovascular event risk prediction
JP2025186325A (ja) 耐糖能異常障害を決定する方法
HK1234105A1 (en) Cardiovascular risk event prediction and uses thereof
HK1234105B (en) Cardiovascular risk event prediction and uses thereof
CA3161906A1 (en) Methods of determining impaired glucose tolerance
HK40078070A (en) Cardiovascular risk event prediction and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170317

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191101

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201016

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210409

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20211014

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211115

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211116

End annual number: 3

Start annual number: 1

PG1601 Publication of registration